EMGEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMGEL (EMGEL).
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
| Metabolism | Metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) isoenzyme; excreted mainly in bile and feces. |
| Excretion | Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination. |
| Half-life | Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 mL/min). |
| Protein binding | 70–80%, primarily to albumin. |
| Volume of Distribution | 0.9–1.1 L/kg; indicates extensive extravascular distribution. |
| Bioavailability | Topical: systemic absorption minimal (approximately 1–5%); oral: 50–60% (first-pass metabolism); intravenous: 100%. |
| Onset of Action | Topical: clinical effect within 30–60 minutes; intravenous: immediate; oral: 30–60 minutes. |
| Duration of Action | 4–6 hours after topical or intravenous administration; 4–8 hours after oral dosing; prolonged in hepatic or renal disease. |
| Brand Substitutes | Lamivir S 150mg/30mg Tablet, Lamistar 150 mg/30 mg Tablet, Lamostad 150 mg/30 mg Tablet, Lamostad Tablet, Stadin Plus 150mg/30mg Tablet, Lamostad 150 mg/40 mg Tablet, Lamivir S 150mg/40mg Tablet |
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
| Dosage form | GEL |
| Renal impairment | No dosage adjustment required for topical use. |
| Liver impairment | No dosage adjustment required for topical use. |
| Pediatric use | Safety and efficacy in children <12 years not established; for children ≥12 years, apply thin layer topically twice daily. |
| Geriatric use | No specific dose adjustment; use caution due to potential skin atrophy in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EMGEL (EMGEL).
| Breastfeeding | Tetracyclines are excreted into breast milk in low concentrations (M/P ratio approximately 0.5-0.8). Theoretical risk of dental staining and bone growth inhibition in nursing infants exists, but absorption of tetracyclines from milk is limited due to chelation with calcium. Caution is advised; alternative therapies preferred. |
| Teratogenic Risk | EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and teeth, causing permanent discoloration and enamel hypoplasia; also associated with impaired skeletal growth and reversible inhibition of bone growth. First-trimester exposure is not associated with major malformations but may affect early bone and tooth development. Use contraindicated after first trimester. |
■ FDA Black Box Warning
No FDA black box warning for topical erythromycin.
| Serious Effects |
["Hypersensitivity to erythromycin or any component of the formulation","Not for use in patients with known hepatic impairment (relative contraindication for systemic use, but topical use is generally safe)"]
| Precautions | ["May cause irritation, burning, stinging, or dryness at application site","Use with caution in patients with known hypersensitivity to erythromycin or any macrolide antibiotic","Superinfection may occur with prolonged use","Potential for bacterial resistance with prolonged use"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver function, renal function, and signs of hypersensitivity. In prolonged therapy, monitor for superinfection. No specific fetal monitoring required if used only in first trimester; if inadvertently used later, fetal ultrasound for skeletal development may be considered. |
| Fertility Effects | No adverse effects on fertility reported in human studies. Animal studies show no significant reproductive toxicity at therapeutic doses. |